GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: NMS-E628 | Rozlytrek® | RXDX-101
                                 entrectinib is an approved drug (Japan and FDA (2019), EMA (2020)) Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Entrectinib is an oral, brain penetrant, receptor tyrosine kinase (RTK) inhibitor that targets solid tumours that harbour activating alterations in NTRK1, NTRK2, NTRK3 (the Trk family RTKs), ROS1 or ALK [6]. NTRK1 fusion proteins are becoming recognised as oncogenic-drivers in NSCLC [3], so the ability of the compound to target these and ALK- and ROS1-rearrangements suggests it has the potential to become a useful oncology agent. More recently entrectinib has been shown to inhibit NLRP3 inflammasome assembly and activation via a direct interaction with NIMA related kinase 7 (NEK7) that disrupts the NLRP3-NEK7 interaction [5]. This discovery suggests a role for entrectinib as an intervention for inflammasome-related diseases. | 
 | |||||||||||||||||||||||||||||||||||
| Download 2D Structure  | |
| Canonical SMILES | Download | 
| Isomeric SMILES | Download | 
| InChI standard identifier | Download | 
| InChI standard key | Download | 
Molecular structure representations generated using Open Babel